Immuron (FRA:ANW) Accounts Payable : €1.02 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Immuron Accounts Payable?

Immuron's Accounts Payable for the quarter that ended in Dec. 2023 was €1.02 Mil.

Immuron's quarterly Accounts Payable increased from Dec. 2022 (€0.08 Mil) to Jun. 2023 (€0.49 Mil) and increased from Jun. 2023 (€0.49 Mil) to Dec. 2023 (€1.02 Mil).

Immuron's annual Accounts Payable declined from Jun. 2021 (€0.48 Mil) to Jun. 2022 (€0.48 Mil) but then increased from Jun. 2022 (€0.48 Mil) to Jun. 2023 (€0.49 Mil).

Immuron Accounts Payable Historical Data

The historical data trend for Immuron's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Accounts Payable Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable

Get a 7-Day Free Trial

0.44

0.10

0.48

0.49

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable	Get a 7-Day Free Trial												0.45	0.48	0.08	0.49	1.02

Immuron Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Immuron Accounts Payable Related Terms

Thank you for viewing the detailed overview of Immuron's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (FRA:ANW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (FRA:ANW) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (FRA:ANW) Headlines

No Headlines